MCID: INV006
MIFTS: 50

Inverted Papilloma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Inverted Papilloma

MalaCards integrated aliases for Inverted Papilloma:

Name: Inverted Papilloma 12 15 73
Inverted Papilloma, Squamous Cell 12
Inverted Squamous Cell Papilloma 73
Papilloma, Inverted 44
Papilloma Inverted 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3179
MeSH 44 D018308
NCIt 50 C3793

Summaries for Inverted Papilloma

MalaCards based summary : Inverted Papilloma, also known as inverted papilloma, squamous cell, is related to urinary tract papillary transitional cell benign neoplasm and inverted transitional papilloma. An important gene associated with Inverted Papilloma is KRT13 (Keratin 13), and among its related pathways/superpathways are Human cytomegalovirus infection and Endometrial cancer. The drugs Fentanyl and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and liver, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and pigmentation

Wikipedia : 76 An inverted papilloma is a type of tumor in which surface epithelial cells grow downward into the... more...

Related Diseases for Inverted Papilloma

Diseases related to Inverted Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
# Related Disease Score Top Affiliating Genes
1 urinary tract papillary transitional cell benign neoplasm 32.7 KRT20 TP53
2 inverted transitional papilloma 32.5 CDKN2A KRT7
3 papilloma 30.7 CCND1 CDKN1B CDKN2A KRT13 KRT20 KRT7
4 verrucous carcinoma 30.5 CCND1 CDKN2A TP53
5 transitional cell carcinoma 30.5 CDKN2A KRT20 KRT7 TP53
6 squamous cell carcinoma 30.4 CCND1 CDKN1B CDKN2A MKI67 SERPINB4 TP53
7 papillary transitional carcinoma 30.4 KRT20 KRT7
8 larynx cancer 30.1 CCND1 CDKN2A TP53
9 nasopharyngeal carcinoma 29.9 CCND1 CDKN2A KRT13 TP53
10 basaloid squamous cell carcinoma 29.8 CDKN2A KRT13 KRT7 TP53
11 bladder cancer 29.6 CCND1 CDKN2A KRT20 MKI67 TP53
12 bladder urothelial carcinoma 29.6 CCND1 CDKN1B KRT20 KRT7 TP53
13 ureter inverted papilloma 12.5
14 frontal sinus inverted papilloma 12.5
15 maxillary sinus inverted papilloma 12.4
16 ethmoid sinus inverted papilloma 12.4
17 sphenoid sinus inverted papilloma 12.4
18 urinary bladder inverted papilloma 12.4
19 renal pelvis inverted papilloma 12.3
20 urethra inverted papilloma 12.3
21 nasal cavity inverting papilloma 12.3
22 squamous cell papilloma 10.6
23 adenosarcoma 10.3 MKI67 TP53
24 embryonal sarcoma 10.3 MKI67 TP53
25 soft tissue sarcoma 10.3 MKI67 TP53
26 anogenital venereal wart 10.3 CDKN2A TP53
27 penile disease 10.3 CDKN2A TP53
28 gastric adenosquamous carcinoma 10.3 CDKN2A TP53
29 cervix small cell carcinoma 10.3 CDKN2A TP53
30 meningeal melanomatosis 10.3 CDKN2A TP53
31 cervix uteri carcinoma in situ 10.3 CDKN2A TP53
32 uterus carcinoma in situ 10.3 CDKN2A TP53
33 dedifferentiated liposarcoma 10.3 CDKN2A TP53
34 adenocarcinoma 10.3
35 brain ependymoma 10.3 MKI67 TP53
36 cll/sll 10.3 CCND1 TP53
37 ischemic fasciitis 10.3 CCND1 CDKN2A
38 bladder squamous cell carcinoma 10.2 CDKN2A TP53
39 benign meningioma 10.2 MKI67 PCNA
40 breast papillomatosis 10.2 CCND1 CDKN2A
41 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
42 gastric lymphoma 10.2 PCNA TP53
43 viral infectious disease 10.2
44 mature teratoma 10.2 PCNA TP53
45 fibrillary astrocytoma 10.2 PCNA TP53
46 tonsil squamous cell carcinoma 10.2 CCND1 CDKN2A
47 ameloblastic carcinoma 10.2 CDKN2A MKI67
48 fanconi anemia, complementation group c 10.2 MT2A PCNA
49 endometrial mucinous adenocarcinoma 10.2 CDKN2A MKI67
50 bowenoid papulosis 10.2 CCND1 CDKN2A

Graphical network of the top 20 diseases related to Inverted Papilloma:



Diseases related to Inverted Papilloma

Symptoms & Phenotypes for Inverted Papilloma

GenomeRNAi Phenotypes related to Inverted Papilloma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 CCND1 MKI67 PCNA

MGI Mouse Phenotypes related to Inverted Papilloma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 8.92 CDKN1B CDKN2A MSX2 TP53

Drugs & Therapeutics for Inverted Papilloma

Drugs for Inverted Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
4
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
5
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
6
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
7
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
8
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
9 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
10 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
12 Anti-Infective Agents Phase 2, Phase 3,Phase 1
13 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
14 Central Nervous System Depressants Phase 3
15 Adjuvants, Anesthesia Phase 3
16 Anesthetics, Intravenous Phase 3
17 Analgesics, Opioid Phase 3
18 Peripheral Nervous System Agents Phase 3,Not Applicable
19 Anesthetics, General Phase 3
20 Analgesics Phase 3
21 Narcotics Phase 3
22 Anesthetics Phase 3
23 Steroid Synthesis Inhibitors Phase 2, Phase 3
24 Hormone Antagonists Phase 2, Phase 3
25 Antifungal Agents Phase 2, Phase 3,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
27 Hormones Phase 2, Phase 3,Phase 1
28 Cytochrome P-450 CYP2C19 Inhibitors Phase 2, Phase 3
29 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
30 Neurotransmitter Agents Phase 3,Not Applicable
31 Cholinergic Agents Phase 3,Not Applicable
32 Autonomic Agents Phase 3,Not Applicable
33 Muscarinic Agonists Phase 3
34 Contraceptive Agents Phase 3
35
Megestrol Phase 3 3562-63-8 19090 3080587
36 Contraceptives, Oral Phase 3
37 Antineoplastic Agents, Hormonal Phase 3
38 Central Nervous System Stimulants Phase 3,Not Applicable
39 Appetite Stimulants Phase 3
40 Histamine Antagonists Phase 3
41 Psychotropic Drugs Phase 3
42 Antidepressive Agents Phase 3
43
Histamine Phosphate Phase 3 51-74-1 65513
44 Antidepressive Agents, Tricyclic Phase 3
45 Antimitotic Agents Phase 3,Phase 2,Phase 1
46
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
47
Indinavir Approved Phase 2 150378-17-9 5362440
48
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
49
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
50
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
3 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
4 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
5 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
6 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
7 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
8 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
9 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
10 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
11 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
12 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
13 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
14 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
15 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
16 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
17 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
18 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
19 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
20 Functional MRI in Finding Hypoxia in Patients Undergoing Chemotherapy and Radiation Therapy for Stage III or Stage IV Head and Neck Cancer Unknown status NCT00896350 Phase 1 chemotherapy
21 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
22 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
23 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
24 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
25 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
26 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
27 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
28 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
29 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
30 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
31 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
32 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
33 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
34 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
35 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
36 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
37 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
38 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
39 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
40 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1 silicon phthalocyanine 4
41 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
42 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074
43 Squamous Cell Carcinoma Antigen Analysis at the University Hospital Ostrava Completed NCT01827423 Not Applicable
44 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib
45 Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00973947 Not Applicable
46 Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer Completed NCT00898300
47 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
48 Immunoreactivity to Cetuximab in Cancer Patients Completed NCT00896896
49 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
50 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 systemic chemotherapy

Search NIH Clinical Center for Inverted Papilloma

Cochrane evidence based reviews: papilloma, inverted

Genetic Tests for Inverted Papilloma

Anatomical Context for Inverted Papilloma

MalaCards organs/tissues related to Inverted Papilloma:

41
Bone, Prostate, Liver, Lung, Cervix, Tongue, Appendix

Publications for Inverted Papilloma

Articles related to Inverted Papilloma:

(show top 50) (show all 605)
# Title Authors Year
1
Clinical features of nasal and sinonasal inverted papilloma associated with malignancy. ( 29548524 )
2018
2
Better surgical outcome by image-guided navigation system in endoscopic removal of sinonasal inverted papilloma. ( 29678350 )
2018
3
Genetic mutation analysis of the malignant transformation of sinonasal inverted papilloma by targeted amplicon sequencing. ( 29779136 )
2018
4
Management of Inverted Papilloma During Holmium Laser Enucleation of the Prostate. ( 29545053 )
2018
5
Optical coherence tomography and confocal laser scanning microscopy as non-invasive tools in the diagnosis of sinonasal inverted papilloma: a pilot study. ( 29737509 )
2018
6
Raman Spectroscopy for Inverted Papilloma: A Proof-of-Concept Study. ( 29763337 )
2018
7
Use of intraoperative negative margins reduces inverted papilloma recurrence. ( 29336292 )
2018
8
Human papillomavirus: An unlikely etiologic factor in sinonasal inverted papilloma. ( 29668071 )
2018
9
Analysis of miRNA expression profiling identifies miR-214-3p as a novel biomarker in sinonasal inverted papilloma. ( 29952653 )
2018
10
Benign inverted papilloma at bladder neck causing acute urinary retention. ( 29942474 )
2018
11
Survivin and cortactin expression in sinonasal schneiderian (inverted) papilloma and associated carcinoma. ( 29644904 )
2018
12
Endoscopic management of maxillary sinus inverted papilloma attachment sites to minimize disease recurrence. ( 29618385 )
2018
13
A Case of Inverted Papilloma of The Mastoid Cavity After Cholesteatoma Surgery. ( 29764790 )
2018
14
Endoscopic Resection of Sinonasal Inverted Papilloma: Systematic Review and Meta-Analysis. ( 29649889 )
2018
15
MR imaging and CT features of oncocytic papilloma of the sinonasal tract with comparison to inverted papilloma. ( 29987980 )
2018
16
Sinonasal inverted papilloma recurrence rates and evaluation of current staging systems. ( 30033450 )
2018
17
An inverted papilloma arising from the middle turbinate and extending to the maxillary sinus ostium. ( 30036423 )
2018
18
Intranasal endoscopic prelacrimal recess approach for maxillary sinus inverted papilloma. ( 30078130 )
2018
19
Resection of Inverted Papilloma of the Maxillary Sinus via a Prelacrimal Recess Approach: A Multicenter Retrospective Analysis of Surgical Efficacy. ( 30251558 )
2018
20
Combination of serum squamous cell carcinoma antigens 1 and 2 as potential diagnostic marker for sinonasal squamous cell carcinoma and inverted papilloma. ( 30376194 )
2018
21
Comprehensive analysis of HPV infection, EGFR exon 20 mutations and LINE1 hypomethylation as risk factors for malignant transformation of sinonasal-inverted papilloma to squamous cell carcinoma. ( 30411788 )
2018
22
A rare presentation of a paediatric sinonasal inverted papilloma. ( 30515294 )
2018
23
Imaging predictors for malignant transformation of inverted papilloma. ( 30515841 )
2018
24
Sinonasal inverted papilloma associated with small cell neuroendocrine carcinoma: A case report and literature review of rare malignancies associated with inverted papilloma. ( 30545727 )
2018
25
Origin site-based staging system of sinonasal inverted papilloma for application to endoscopic sinus surgery. ( 30554455 )
2018
26
Management of maxillary sinus inverted papilloma via endoscopic partial medial maxillectomy with an inferior turbinate reversing approach. ( 28936551 )
2017
27
Long-term follow-up of a patient with malignant transformation of inverted papilloma into sinonasal undifferentiated carcinoma. ( 29070275 )
2017
28
Surgical management of inverted papilloma; a single-center analysis of 247 patients with long follow-up. ( 29262865 )
2017
29
Association of Krouse Classification for Sinonasal Inverted Papilloma With Recurrence: A Systematic Review and Meta-analysis. ( 28973390 )
2017
30
The analysis of expression of p16 protein in group of 53 patients treated for sinonasal inverted papilloma. ( 28479047 )
2017
31
Malignant transformation of nasal inverted papilloma into sarcomatoid carcinoma. ( 29512804 )
2017
32
Bone involvement: Histopathological evidence for endoscopic management of sinonasal inverted papilloma. ( 28722237 )
2017
33
Management of inverted papilloma: review. ( 28179032 )
2017
34
"TuNa-saving" endoscopic medial maxillectomy: a surgical technique for maxillary inverted papilloma. ( 28374054 )
2017
35
Recurrence of Sinonasal Inverted Papilloma Following Surgical Approach: A Meta-Analysis. ( 28490410 )
2017
36
Etiology of sinonasal inverted papilloma: A narrative review. ( 29204580 )
2017
37
Risk Factors of Recurrence and Malignant Transformation of Sinonasal Inverted Papilloma. ( 29250552 )
2017
38
Dysphagia caused by an inverted papilloma. ( 29237672 )
2017
39
Sinonasal undifferentiated carcinoma originating from inverted papilloma: A case report. ( 29137081 )
2017
40
Inverted papilloma of middle ear and temporal bone. ( 28233515 )
2017
41
Sinonasal Inverted Papilloma: Risk Factors for Local Recurrence After Surgical Resection. ( 28421830 )
2017
42
Different characteristics of a single sinonasal inverted papilloma from sequential PET-CT: A case report. ( 29384975 )
2017
43
Multifocal sinonasal inverted papilloma with middle ear involvement. ( 28966465 )
2017
44
Expression pattern of estroprogestinic receptors in sinonasal inverted papilloma. ( 28473663 )
2017
45
Endoscopic surgery of a sinonasal inverted papilloma: Surgical strategy, follow-up, and recurrence rate. ( 28234155 )
2017
46
Postoperative long-term morbidity of extended endoscopic maxillectomy for inverted papilloma. ( 28687815 )
2017
47
Ossifying inverted papilloma and ossifying polypA of the sinonasal tract: comparison ofA CTA andA MRI features. ( 27773333 )
2017
48
The clinical behavior of sinonasal inverted papilloma with cellular dysplasia: case series and review of the literature. ( 28597339 )
2017
49
The rapid change in sinonasal inverted papilloma incidence - the epidemiological analysis. ( 28485293 )
2017
50
Complete response of skull base inverted papilloma to chemotherapy: Case report. ( 28583236 )
2017

Variations for Inverted Papilloma

Cosmic variations for Inverted Papilloma:

9 (show all 17)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM496 HRAS urinary tract,bladder,papilloma,inverted c.181C>A p.Q61K 11:533875-533875 16
2 COSM714 FGFR3 urinary tract,bladder,papilloma,inverted c.742C>T p.R248C 4:1801837-1801837 16
3 COSM29438 FGFR3 urinary tract,bladder,papilloma,inverted c.1921G>A p.D641N 4:1806135-1806135 16
4 COSM29432 FGFR3 urinary tract,bladder,papilloma,inverted c.775C>T p.L259L 4:1801870-1801870 16
5 COSM29431 FGFR3 urinary tract,bladder,papilloma,inverted c.745T>A p.S249T 4:1801840-1801840 16
6 COSM29434 FGFR3 urinary tract,bladder,papilloma,inverted c.796G>A p.V266M 4:1801891-1801891 16
7 COSM29437 FGFR3 urinary tract,bladder,papilloma,inverted c.1881G>T p.E627D 4:1806095-1806095 16
8 COSM29439 FGFR3 urinary tract,bladder,papilloma,inverted c.1927C>G p.H643D 4:1806141-1806141 16
9 COSM29436 FGFR3 urinary tract,bladder,papilloma,inverted c.1236C>T p.H412H 4:1804490-1804490 16
10 COSM29440 FGFR3 urinary tract,bladder,papilloma,inverted c.1957A>C p.N653H 4:1806171-1806171 16
11 COSM715 FGFR3 urinary tract,NS,papilloma,inverted c.746C>G p.S249C 4:1801841-1801841 15
12 COSM10742 TP53 urinary tract,bladder,papilloma,NS c.578A>G p.H193R 17:7674953-7674953 9
13 COSM43814 TP53 urinary tract,bladder,papilloma,NS c.587G>C p.R196P 17:7674944-7674944 9
14 COSM43749 TP53 urinary tract,bladder,papilloma,NS c.595G>A p.G199R 17:7674936-7674936 9
15 COSM10801 TP53 urinary tract,bladder,papilloma,NS c.404G>A p.C135Y 17:7675208-7675208 9
16 COSM44602 TP53 urinary tract,bladder,papilloma,NS c.562C>G p.L188V 17:7674969-7674969 9
17 COSM718 FGFR3 urinary tract,bladder,papilloma,NS c.1118A>G p.Y373C 4:1804372-1804372 9

Expression for Inverted Papilloma

Search GEO for disease gene expression data for Inverted Papilloma.

Pathways for Inverted Papilloma

Pathways related to Inverted Papilloma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 CCND1 CDKN1B CDKN2A PCNA TP53
2
Show member pathways
12.71 CCND1 CDKN1B CDKN2A PCNA TP53
3 12.68 CCND1 CDKN1B CDKN2A TP53
4
Show member pathways
12.62 CCND1 CDKN1B CDKN2A TP53
5
Show member pathways
12.6 CCND1 CDKN1B CDKN2A TP53
6
Show member pathways
12.54 CCND1 CDKN1B PCNA TP53
7 12.38 CCND1 CDKN1B CDKN2A TP53
8
Show member pathways
12.35 CCND1 CDKN1B CDKN2A PCNA TP53
9
Show member pathways
12.26 CCND1 CDKN1B PCNA TP53
10
Show member pathways
12.23 CCND1 CDKN1B CDKN2A TP53
11
Show member pathways
12.2 CCND1 CDKN1B CDKN2A TP53
12 12.13 CCND1 CDKN1B CDKN2A TP53
13
Show member pathways
12.08 CCND1 CDKN1B CDKN2A
14 12.06 CCND1 CDKN2A MSX2 PCNA TP53
15 12.03 CCND1 CDKN2A TP53
16 11.99 CCND1 CDKN1B TP53
17 11.88 CCND1 CDKN1B TP53
18
Show member pathways
11.8 CDKN1B PCNA TP53
19 11.77 CCND1 CDKN1B CDKN2A TP53
20 11.75 CCND1 CDKN1B TP53
21 11.71 CCND1 CDKN1B CDKN2A TP53
22 11.71 CCND1 CDKN1B CDKN2A PCNA TP53
23 11.65 CDKN1B CDKN2A PCNA TP53
24 11.64 CDKN1B MKI67 PCNA
25 11.62 CCND1 CDKN2A TP53
26 11.57 CCND1 CDKN1B CDKN2A MKI67 PCNA TP53
27 11.44 CCND1 MT2A TP53
28 11.4 CCND1 CDKN1B PCNA TP53
29 11.39 CCND1 CDKN2A TP53
30 11.37 CCND1 CDKN1B TP53
31 11.3 CCND1 PCNA TP53
32 11.14 CCND1 PCNA TP53
33 11.13 PCNA TP53
34 10.98 CDKN2A TP53
35
Show member pathways
10.98 CDKN2A TP53

GO Terms for Inverted Papilloma

Cellular components related to Inverted Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.61 CCND1 CDKN1B CDKN2A KRT13 KRT20 KRT7
2 intermediate filament GO:0005882 9.33 KRT13 KRT20 KRT7
3 nucleus GO:0005634 9.32 CCND1 CDKN1B CDKN2A KRT13 KRT7 MKI67

Biological processes related to Inverted Papilloma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.8 CDKN1B CDKN2A MSX2 TP53
2 cell cycle arrest GO:0007050 9.65 CDKN1B CDKN2A TP53
3 negative regulation of cell growth GO:0030308 9.61 CDKN1B CDKN2A TP53
4 cornification GO:0070268 9.58 KRT13 KRT20 KRT7
5 cell cycle GO:0007049 9.55 CCND1 CDKN1B CDKN2A MKI67 TP53
6 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.54 CCND1 CDKN1B
7 response to cadmium ion GO:0046686 9.52 CDKN1B PCNA
8 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.51 CDKN1B CDKN2A
9 response to estradiol GO:0032355 9.5 CCND1 CDKN1B PCNA
10 negative regulation of phosphorylation GO:0042326 9.46 CDKN1B CDKN2A
11 G1/S transition of mitotic cell cycle GO:0000082 9.43 CCND1 CDKN1B CDKN2A
12 replicative senescence GO:0090399 9.37 CDKN2A TP53
13 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
14 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 8.8 CDKN1B PCNA TP53

Molecular functions related to Inverted Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.56 CCND1 CDKN1B CDKN2A TP53
2 enzyme binding GO:0019899 9.46 CCND1 PCNA SERPINB4 TP53
3 histone acetyltransferase binding GO:0035035 9.32 PCNA TP53
4 transcription factor binding GO:0008134 9.26 CCND1 CDKN2A MSX2 TP53
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN1B CDKN2A

Sources for Inverted Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....